<DOC>
	<DOCNO>NCT01493479</DOCNO>
	<brief_summary>90Y Ibritumomab tiuxetan ( zevalin ) demonstrate consistently high response rate patient receive previous treatment lymphoma . More two-thirds patient achieve CR go experience durable remission last year . Despite highly promise clinical result radioimmunotherapy ( RIT ) relapse follicular lymphoma little data use RIT previously untreated follicular lymphoma . The objective trial evaluate safety efficacy two fraction Zevalin patient previously untreated follicular lymphoma Phase II study .</brief_summary>
	<brief_title>Phase II Study Fractionated 90Y Ibritumomab Tiuxetan ( Zevalin ) Radioimmunotherapy Initial Therapy Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must histologically confirm CD20 +ve follicular lymphoma grade I IIIa . Patients least one follow symptom require initiation treatment : ( outline modify BNLI/GELF criterion ) Nodal mass &gt; 7cm great diameter B symptom Elevated serum LDH beta2microglobulin involvement least 3 nodal site ( diameter &gt; 3 cm ) symptomatic splenic enlargement compressive syndrome Patients must ECOG performance status less equal 2 anticipated survival least 6 month . Patients must absolute granulocyte count 1,500/mm3 , platelet count 100,000/mm3 post 4 week unlabelled Rituximab . A hemoglobin &gt; = 8.0 g/dl Patients must adequate renal function ( define calculate creatinine clearance &gt; 30 ml/mn ) , hepatic function ( defined total bilirubin &lt; 1.5 time upper limit normal ) , hepatic transaminase ( define AST &lt; 5 time upper limit normal ) Patients must give informed consent prior study entry . Patients mean &gt; 20 % intratrabecular marrow space involve lymphoma bone marrow biopsy follow induction Rituximab therapy . Transformed follicular lymphoma discordant lymphoma Patients active obstructive hydronephrosis . Patients initial disease bulk great 10cm . Patients evidence active infection require i.v . antibiotic time study entry . Patients congestive heart failure stage III IV NYHA classification , myocardial infraction unstable angina within 6 month serious illness would preclude evaluation . Patients leave VEF &lt; 40 % Patients large pleural peritoneal effusion . Patients know HIV infection active HBV ( HbsAg positivity ) HCV infection . Known Hypersensitivity murine antibody proteins Patients pregnant breastfeeding . Male female patient must agree use effective contraception 12 month follow 90Yibritumomab tiuxetan antibody therapy . Patients prior malignancy lymphoma , except adequatelytreated skin cancer , cervical cancer situ , cancer patient diseasefree 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>